文献速递骨软组织肉瘤与黑色素瘤

Encorafenib联合binimetinib对比维莫非尼或Encorafenib单药治疗BRAF突变黑色素瘤的III期COLUMBUS研究

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-03-21

COLUMBUS是一项多中心开放标签随机III期试验,纳入577例BRAF V600突变晚期黑色素瘤患者,比较Encorafenib联合binimetinib、Encorafenib单药与维莫非尼的疗效与安全性。

要点

  • 联合组常见3-4级不良事件为γ-谷氨酰转移酶升高、肌酸磷酸激酶升高和高血压。
  • 联合方案可能成为BRAF突变黑色素瘤的新治疗选择,且耐受性优于单药。

核心结论

  • Encorafenib联合binimetinib及Encorafenib单药相比维莫非尼均显示更优疗效。
  • 联合方案总体耐受性优于Encorafenib单药或维莫非尼。
  • 联合方案可能成为BRAF突变黑色素瘤的新治疗选择。

研究设计与样本

  • COLUMBUS为两部分、随机、开放标签、III期研究,在28个国家162家医院开展。
  • 第一部分将577例BRAF V600E或V600K突变晚期黑色素瘤患者按1:1:1随机分配至联合组(n=192)、Encorafenib组(n=194)或维莫非尼组(n=191)。
  • 主要终点为盲法独立中心评审的PFS(联合组 vs 维莫非尼组),疗效分析采用意向性治疗人群。

主要发现

  • 联合组发生率>5%的3-4级不良事件包括γ-谷氨酰转移酶升高(18/192,9%)、肌酸磷酸激酶升高(13/192,7%)和高血压(11/192,6%)。
  • Encorafenib组常见3-4级不良事件为掌跖红斑感觉异常综合征(26/192,14%)、肌痛(19/192,10%)和关节痛(18/192,9%);维莫非尼组为关节痛(11/186,6%)。
  • 除联合组1例死亡被研究者认为可能与治疗相关外,无其他治疗相关死亡。

关键数值与推荐

  • 入组标准:≥18岁,组织学确诊局部晚期(AJCC IIIB、IIIC或IV期)不可切除或转移性皮肤黑色素瘤或原发灶不明黑色素瘤,BRAF V600E或V600K突变,ECOG体能状态0或1,初治或既往一线免疫治疗后进展。
  • 给药方案:联合组口服Encorafenib 450 mg每日一次+binimetinib 45 mg每日两次;Encorafenib组口服300 mg每日一次;维莫非尼组口服960 mg每日两次。

临床怎么用

  • 对于BRAF V600突变晚期黑色素瘤,Encorafenib联合binimetinib可作为新的靶向治疗选择。
  • 治疗期间需监测γ-谷氨酰转移酶、肌酸磷酸激酶和血压等联合方案常见毒性。

局限性

  • 本研究为开放标签设计。
  • 原文未报告总生存期数据。
  • 第二部分结果将另行发表,未纳入本报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma. METHODS: COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technology to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib versus vemurafenib. Efficacy analyses were by intention-to-treat. Safety was analysed in patients who received at least one dose of study drug and one postbaseline safety assessment. The results of part 2 will be published separately. This study is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38. FINDINGS: Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191). With a median follow-up of 16·6 months (95% CI 14·8-16·9), median progression-free survival was 14·9 months (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 months (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001). The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients). There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator. INTERPRETATION: Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib. Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib. Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma. FUNDING: Array BioPharma, Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018. PMID: 29573941. doi:10.1016/S1470-2045(18)30142-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。